Using patents to restrict harmful applications of CRISPR


The new CRISPR gene-editing technology is an incredible tool, but it could be used for ethically-troubling procedures like human eugenics, modification of human germline cells, genetically-modified crops, gene drives to wipe out species and on and on and on. How can its uses be restricted?

Writing in Nature Biotechnology, several academics from Baylor College of Medicine in Houston and New York Law School, suggest that ethical licencing by patent holders is a necessary complement to government legislation.

The Broad Institute, in Boston, owns the foundational patents for the CRISPR process. It recently licensed the technology to chemical giant Monsanto with three provisos: (1) not to conduct gene drives, (2) not create sterile “terminator” seeds which farmers would be forced to buy new every year, and (3) not to conduct research to commercialize tobacco products which would add to the public health burden of smoking.

Two years ago, it also licensed CRISPR to Editas Medicine provided that Editas did not use it to to modify human germ cells or embryos or to modify animal cells for the creation or commercialization of organs suitable for transplantation into humans.

“Innovators should follow the Broad Institute’s lead and adopt the practice of using patent licenses to restrict socially harmful applications of their technologies. To be clear, we do not mean to suggest that licensing bans are preferable to, or should be used to the exclusion of, policymaking or professional standards setting. Rather, we believe that the promotion of private efforts as a complement to public efforts is worthy of serious consideration,” says Baylor ethicist Christi Guerrini. 




MORE ON THESE TOPICS | crispr, patents

This article is published by Michael Cook and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

 
 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 
comments powered by Disqus